TB Alliance's REMox TB program leverages ACTG sites to advance testing of improved TB treatments November 15, 2011, Durban, South Africa— The TB Alliance announces the launch of a collaboration with the National Institute of Allergy and Infectious Diseases' (NIAID)…
New data released by the Treatment Action Group (TAG) and the Stop TB Partnership finds that in 2010 the world spent just $617 million in tuberculosis (TB) research and development (R&D), or 0.3% less than 2009 funding levels—the first time TAG documents no growth since it began tracking TB research investments in 2005.
Tuberculosis Research and Development: 2010 Report on Tuberculosis Research Funding trends, 2005-2009: 2nd Edition By Eleonora Jimenez March 2011 - This is the 2nd Edition of the Stop TB Partnership and Treatment Action Group’s 2010 report on funding trends for…
A follow up to the letter of May 3, 2011, regarding the steps being taken by the Coordinating Board to reduce the conflict of interest in the Stop TB Partnership’s relationship with the World Health Organization (WHO), improve transparency and accountability in the operations and activities of the Partnership, and strengthen the Partnership’s ability to fulfill its mandate.
By Claire Wingfield It is estimated that of the nine million new cases of tuberculosis (TB) each year, one million occur among children under the age of 15. Yet advocacy for prevention, diagnosis, and treatment of TB in children has…
By Coco Jervis and Sue Perez Negligible Increases for AIDS, TB, Viral Hepatitis Treatment and Research On Monday, February 1, 2010, President Barack Obama unveiled his fiscal year (FY) 2011 budget to the U.S. Congress. Global health programs were allocated…
By Javid Syed BOTUSA study strongly supports continuous preventive IPT for people with HIV Tuberculosis (TB) remains the leading cause of death among people living with HIV. The World Health Organization’s 2009 report Global Tuberculosis Control: Epidemiology, Strategy, Financing reported…
By Claire Wingfield After 40 years of scientific stagnation, it is beginning to be an exciting time in tuberculosis treatment research. Tuberculosis (TB) is the leading killer of people with HIV worldwide, accounting for more than quarter of all HIV…
By Claire Wingfield After nearly 50 years, there is finally something to get excited about in tuberculosis (TB) drug development. Tibotec’s TMC207—the first compound from a novel class of TB drugs, the diarylquinolines—will likely be submitted to the U.S. Food…
by Javid Syed On December 8, 2010 the World Health Organization (WHO) endorsed the use of the new Xpert® MTB/RIF test as the initial test offered to people suspected of having HIV-associated TB or multidrug-resistant (MDR) TB. The test, developed…